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Leprosy elimination—a virtual phenomenon or a reality?
Diana N J Lockwood
Why are evidence based policies not guiding the World Health Organization’s leprosy elimination
campaign, asks Diana Lockwood
Leprosy is an infectious disease but it has many
features in common with neurodegenerative dis›
orders. It results in a chronic neurological illness,
which is progressive unless treated; frequently
produces long term disability; and is associated with
high levels of stigma. As it has a known infective agent,
Mycobacterium leprae, there is the possibility of disease
control. Multidrug treatment with the antibiotic com›
bination rifampicin, dapsone, and clofazimine is
highly effective in curing infection, with relapse
rates of 1%.1 It was hoped that having effective anti›
biotics would permit disease control and thus the con›
cept of leprosy elimination developed. “Leprosy
elimination by the year 2000” was first proposed in
1986 and at the 44th World Health Assembly in 1991
modified by the addendum “as a public health
problem,” defined as less than one case per 10 000
population.2 The leprosy elimination campaign has
had some notable successes but also illustrates the
epidemiological, medical, and political problems of
the elimination concept.
Controlling and treating leprosy
Leprosy is a complex mycobacterial disease whose
manifestations and complications are determined by
the immune response. Many patients experience
immune mediated nerve damage, which may occur
before, during, or after treatment. Recent field based
cohort studies have shown that at diagnosis many
patients already have established nerve damage; rates
vary from 20% in Bangladesh to 56% in Ethiopia,3 4
and these patients have a worse prognosis for disability.
Up to 30% of multibacillary patients have acute
inflammatory episodes (reactions) affecting skin and
nerves. Prednisolone is used to suppress reactions and
ameliorates acute nerve damage in about 60% of
patients.5 Anaesthesis and paresis in the hands and feet
put them at risk of secondary damage from trauma
and infection, which cause the highly visible deformi›
ties of leprosy (fig 1). The purpose of controlling
leprosy is to reduce the rate and severity of disability.
The key to effective management of leprosy is early
diagnosis and treatment and early recognition and
management of nerve damage, combined with
effective health education.
What has the elimination campaign achieved?
People and governments were mobilised, leprosy pro›
grammes were revitalised, and drug treatment for lep›
rosy was provided free of cost by the Sasakawa
Foundation through the World Health Organization.
Imaginative programmes were devised, such as
monthly drug delivery circuits by paramedical
workers to supervise taking the monthly components
of multidrug therapy. Morale among patients and
workers improved. Eleven million patients have been
given multidrug therapy. The number of registered
patients fell from 5 million in 1985 to 0.7 million in
2001. But this fall was almost entirely attributable to a
change of case definition that includes patients only
during the course of multidrug therapy—that is,
those with active infection.6 Patients with ongoing
complications or disabilities due to the disease are
excluded.
In 2001 WHO claimed that leprosy had been elimi›
nated “at a global level,” even though 719 330 new
patients were registered in 2000 (fig 2).7 In the 27 top
countries where leprosy is endemic, the incidence did
not fall between 1985 and 1999, and in the six countries
that account for 88% of new cases the numbers and inci›
dence of new cases are rising (figs 3 and 4).9 Children
comprise 15% of cases, indicating that active transmis›
sion continues. WHO has now rescheduled elimination
for 2005. Integration of previous leprosy›only pro›
grammes into primary health care is the preferred
model. Leprosy is not an easy disease to diagnose, and
patients seen at peripheral clinics will go undiagnosed,
thus apparently reducing the incidence of the disease
further.
Policy changes should be evidence based
The enthusiasm of the WHO for simplifying leprosy
management threatens the achievements of the elimi›
WHO clinical classification for field
programmes1
• Paucibacillary single lesion leprosy (one skin lesion)
• Paucibacillary (two to five skin lesions)
• Multibacillary (more than five skin lesions)
Neurological assessment and slit skin smears do not
contribute to this classification.
Summary points
Leprosy is a leading cause of neurological
disability
The World Health Organization’s leprosy
elimination campaign has treated 11 million
patients, but case numbers are still rising in the
major countries where leprosy is endemic
New methods for diagnosis and treatment
proposed by the WHO risk missing disease and
undertreating patients, and an opportunity for
implementing evidence based policies may be
missed
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nation campaign. Numerous policy changes have ema›
nated from the WHO for direct implementation in the
field without prior research. Skin smears, essential for
identifying patients with high bacterial loads, have
been discontinued and the duration of multidrug
therapy for multibacillary patients has been reduced
from 24 months to 12 months despite evidence that
patients with high bacterial loads are at greater risk of
relapse.10
The latest WHO document,The Final Push Strategy to
Eliminate Leprosy as a Public Health Problem:Questions and
Answers, proposes a new treatment, accompanied multi›
drug therapy.11 Patients will be given all the medicines
for the full six or 12 month course of treatment at their
first, diagnostic, visit with the proviso that someone close
to the patient will take responsibility for helping the
patient complete the course of treatment. This is a curi›
ous reversal of policy. Ten years ago the strength of the
leprosy programme lay in the monthly supervision of
medication, which also meant that nerve damage was
picked up early and health education could be ongoing.
The new policy contrasts with that of directly observed
treatment (DOTS) in the tuberculosis programmes.
Another major policy change relates to the
recognition and management of reactions (acute
inflammatory episodes). The document minimises the
need for giving steroids for leprosy reactions, stating,
incorrectly, that most leprosy reactions can be control›
led by non›steroidal drugs. There are no data on the
effectiveness of non›steroidal drugs in leprosy reac›
tions. The document making these proposals, which
will guide policy in leprosy endemic countries, has no
authors and no references to published work and states
that it is not a formal publication of the WHO. The
WHO Technical Advisory Group has now recom›
mended a further untested policy change: that all lep›
rosy patients, regardless of disease type, be given a six
month triple drug regimen.12 This would simplify
leprosy treatment but give 60% of patients a third drug
that they do not need, and it would undertreat patients
with a high bacterial load. It is proposed that this treat›
ment be implemented without a formal trial.
Ominously, the document later notes that “a study of
which the results will only be published in five years will
not help elimination efforts.” Good research is needed
to underpin leprosy policies, particularly since integra›
tion will increase the difficulties of doing field based
research.
Policies for leprosy control can be evidence based,
as has been shown by an expert group convened by the
International Leprosy Association this year. The group
produced evidence based graded recommendations
on issues relating to leprosy control, diagnosis and
classification, chemotherapy, nerve damage and reha›
bilitation, and sustainability of leprosy services
(www.lepra.org.uk/).13 Simplifying diagnosis has been
considered by both the WHO and the evidence based
group; the WHO document states that in 70% of
patients, diagnosis can be made by a single sign: an
anaesthetic skin patch. The evidence based group
found that the other 30% are multibacillary patients,
who are more likely to be infectious and to develop
nerve damage.
Multisectorial partnerships
In 1999 the WHO created the Global Alliance to
Eliminate Leprosy (GAEL) in partnership with the
Nippon Foundation, the drug company Novartis,
DANIDA (Danish agency for development assistance),
and ILEP (International Federation of Anti›Leprosy
Associations, the umbrella organisation of the non›
governmental organisations for leprosy) to provide
multidrug therapy for all patients. But when ILEP
members questioned the policies being promoted by
the global alliance they were excluded from the
partnership. WHO staff have subsequently outlined the
WHO’s position on a web based leprosy discussion
group (noto@cefpas.it). The differences may arise in
part from different perspectives. WHO has a global
public health view, treating populations, whereas the
leprosy non›governmental organisations have a
stronger focus on treating individuals. If integration is
to succeed then all available leprosy expertise will need
to be mobilised and to work together in a
multisectorial approach, and the expertise of the non›
governmental organisations will be invaluable.
Elimination is not eradication
The elimination of leprosy will be a virtual
phenomenon—elimination of registered cases through
Fig 1 Nerve impairment with secondary damage. The boy has bilateral ulnar and median
nerve involvement affecting the hands, with small muscle wasting and finger clawing; he has
lost temperature sensation and burnt his hands when standing by a fire
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very short treatment regimens without reducing the
number of new cases. The concept of elimination at a
prevalence of one case per 10 000 population is a diffi›
cult concept to understand, and many people confuse
it with eradication. There is no evidence that reaching
this predefined prevalence will reduce transmission,
incidence, or the annual number of new cases. Who
needs this prize, and must it be delivered at all costs?
The elimination campaign has shown how difficult it
will be to eliminate leprosy in countries where it is
highly endemic. The biology of the organism and the
disease mitigate against easy control of transmission.
Lepromatous patients are highly infectious through
their nasal secretions; the organism can survive many
months outside a human host; up to 5% of the popula›
tion in leprosy endemic areas are nasal carriers of M
leprae DNA.14 Lepromatous disease has a mean clinical
incubation time of 10 years.15
If the WHO believes its own rhetoric about
eliminating leprosy, then governments of countries
where leprosy is endemic may believe it too and
disband their control programmes and disperse their
skilled staff. But they may be left with many
unanswered questions. Who will provide drug treat›
ment after 2005? Who will train the primary health
care workers once the vertical programmes have been
disbanded? What plans are being made for the long
term care of patients with nerve damage, who will con›
tinue to present for many years to come? In the 1960s
tuberculosis and malaria were pronounced defeated;
now we face global emergencies in control and
management for both diseases. It would be tragic to see
this cycle repeated with leprosy.
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Fig 3 Prevalence and incidence of leprosy in India, 1984›2000
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Fig 4 Incidence of leprosy in the top six endemic countries, 1995
and 2000
One hundred years ago
The classics in preliminary examinations
Sir › Your article in the British Medical Journal of February 15th,
and Sir William Gairdner’s letter of the same date, defend Latin
learning as a necessity for the proper use of English. It is on that
ground that both you and he require its retention.
That view I disbelieve. Newspapers show us that plenty of men
who have had a classical education write execrable English. It is
equally certain that many write excellently who have had no such
training. To write well is to write clearly, to write clearly it chiefly
needs to think clearly, and clear thinking is to be gained by many
other studies than the learning of Latin.
All men allow that the classics are a fine mental training, and an
introduction to cultivated pleasures. That is, however, no reason
for claiming that they stand alone. When you and I, sir, were
young they formed the only liberal education. It seems doubtful,
to judge by the present dispute, if the education was as liberal as
we supposed.—I am, etc.,
Wimpole Street, W., Feb. 17th.
W. P. HERRINGHAM.
(BMJ 1902;i:485)
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